SecBot SecBot
8-K ·Filed Aug 13, 2026

PDSB

PDS Biotechnology Corp
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001140361-26-032650
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The cash runway of $5.6M at current burn rate (~$3.3M/quarter operating expenses) provides less than 2 quarters of liquidity, making a dilutive equity financing or partnership deal for PDS0101 highly probable in the near term. The Phase 3 discontinuation removes a key catalyst; PDS0301 data is early-stage (Phase 2 mCRC, n=9). Traders should watch for financing announcements and PDS0301 partnership or clinical updates.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

PDSB drug pipeline →

PDS0301

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
Next catalyst
None dated

What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.2332
T+0 close · Aug 13, 2026 · via day close
Latest settled
+427.44%
T+60 · $1.23
Vs SPY
+432.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $0.2332entry
  2. T+1 · 3mo ago −1.11%α −0.92% · $0.2306
  3. T+5 · 3mo ago −10.42%α −8.46% · $0.2089
  4. T+20 · 2mo ago +26.46%α +28.20% · $0.2949
  5. T+60 · 11d ago +427.44%α +432.92% · $1.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a strategic refocus to prioritize PDS0301, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101. Cash burned to $5.6M from $21.7M at year-end, with negative working capital of -$5.3M, raising going-concern risk. The pipeline pivot and cash runway depletion are the primary stock-moving events, outweighing the earnings miss for this pre-revenue biotech.

Key Financial Metrics

EPS
−$0.18
est −$0.13 · -38.5%
Rating
strong miss

Key Facts

  • Net loss of $9.8M ($0.18/share) for Q2 2026 vs $9.4M ($0.21/share) in Q2 2025
  • EPS of -$0.18 missed consensus of -$0.13 by 42.1%
  • Cash balance fell to $5.6M as of June 30, 2026, from $21.7M at March 31, 2026
  • Working capital turned negative to -$5.3M from positive $18.8M at year-end 2025
  • Company ceased internal investment in PDS0101, discontinuing VERSATILE-003 Phase 3 trial
  • Strategic refocus prioritizes PDS0301 (formerly PDS01ADC) as lead development program
  • Long-term debt retired to $0 from $11.7M at year-end 2025
  • Total stockholders' equity negative at -$3.6M vs positive $9.3M at year-end 2025

Financial Impact

Cash burn of ~$16.1M in H1 2026; $5.6M remaining cash likely insufficient for more than one quarter of operations without financing

cashworking capitalequitydilution

Risk Factors

  • Cash runway insufficient to fund operations beyond Q4 2026 without additional capital
  • Discontinuation of VERSATILE-003 Phase 3 trial eliminates near-term regulatory catalyst for PDS0101
  • PDS0301 is early-stage (Phase 2, single-center, n=9) with no confirmed regulatory pathway
  • Negative stockholders' equity (-$3.6M) and working capital deficit (-$5.3M) signal financial distress
  • Potential Nasdaq delisting risk if stock price remains below $1.00

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-032650
Document: ef20080122_8k.htm0001140361-26-032650
Document: 0001140361-26-032650-index-headers.html0001140361-26-032650
Document: 0001140361-26-032650-index.html0001140361-26-032650
Document: 0001140361-26-032650.txt0001140361-26-032650
8-K Data (Synthetic)0001140361-26-032650

Track record

28 reports on PDSB

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026